Literature DB >> 15181664

Human parathion poisoning. A toxicokinetic analysis.

Florian Eyer1, Veronika Meischner, Daniela Kiderlen, Horst Thiermann, Franz Worek, Michael Haberkorn, Norbert Felgenhauer, Thomas Zilker, Peter Eyer.   

Abstract

The mortality rate of suicidal parathion poisoning is particularly high, the onset of fulminant cholinergic signs, and the patients frequently present to the emergency physician with life-threatening symptoms. Despite this uniformity, subsequent clinical course differs significantly among patients, mostly not as a result of different delays in treatment or insufficiency of primary care. Probably, the differences depend on the amount of poison absorbed and/or the disposition of the active poison, paraoxon. We followed the toxicokinetics of parathion and tried to quantify the actual poison load. To this end, we monitored parathion-intoxicated patients (patients requiring artificial ventilation) for plasma levels of parathion and paraoxon along with the activity of erythrocyte acetylcholinesterase and its reactivatability. Plasma obidoxime concentrations were followed as well as the cumulative urinary para-nitrophenol conjugate excretion as a measure of total poison load. All patients received a standard obidoxime scheme of a 250 mg bolus dose intravenously, followed by continuous infusion with 750 mg per 24 hours as long as reactivation could be expected (usually 1 week). All other treatment was instituted as judged by the physician. It was recommended to use atropine at low doses to achieve dry mucous membranes, no bronchoconstriction and no bradycardia. Usually 1-2 mg/h were sufficient. Seven selected cases are presented exemplifying toxicokinetic peculiarities. All patients were severely intoxicated, while the amount of parathion absorbed varied widely (between 0.12 and 4.4 g; lethal dose 0.02-0.1 g) and was generally much lower than anticipated from the reports of relatives. It remains open whether the discrepancies between reports and findings were due to exaggeration or to effective decontamination (including spontaneous vomiting, gastric lavage and activated charcoal). Absorption of parathion from the gastrointestinal tract was sometimes retarded, up to 5 days, resulting in fluctuating plasma profiles. The volume of distribution at steady-state (Vdss) of parathion was around 20 L/kg. Post-mortem analysis in one patient revealed a 66-fold higher parathion concentration in fat tissue compared with plasma, 16 days after ingestion. Biotransformation of parathion varied widely and was severely retarded in one patient receiving fluconazole during worsening of renal function, while phenobarbital (phenobarbitone) sedation (two cases) had apparently no effect. The proportion of plasma parathion to paraoxon varied from 0.3-30, pointing also to varying paraoxon elimination, as illustrated by one case with particularly low paraoxonase-1 activity. Obidoxime was effective at paraoxon concentrations below 0.5 microM, provided aging was not too advanced. This concentration correlated poorly with the paration concentration or the poison load. The data are discussed in light of the pertinent literature.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15181664     DOI: 10.2165/00139709-200322030-00003

Source DB:  PubMed          Journal:  Toxicol Rev        ISSN: 1176-2551


  26 in total

1.  Non-muscarinic therapeutic targets for acute organophosphorus poisoning.

Authors:  Christopher Rosenbaum; Steven B Bird
Journal:  J Med Toxicol       Date:  2010-12

2.  Intralipid fat emulsion decreases respiratory failure in a rat model of parathion exposure.

Authors:  Courtney Dunn; Steven B Bird; Romolo Gaspari
Journal:  Acad Emerg Med       Date:  2012-05       Impact factor: 3.451

Review 3.  Management of acute organophosphorus pesticide poisoning.

Authors:  Darren M Roberts; Cynthia K Aaron
Journal:  BMJ       Date:  2007-03-24

4.  Aerosolized recombinant human butyrylcholinesterase delivered by a nebulizer provides long term protection against inhaled paraoxon in macaques.

Authors:  Yvonne Rosenberg; James Fink; Ronan MacLoughlin; Tara Ooms-Konecny; Dennis Sullivan; William Gerk; Lingjun Mao; Xiaoming Jiang; Jonathan Lees; Lori Urban; Narayanan Rajendran
Journal:  Chem Biol Interact       Date:  2019-06-12       Impact factor: 5.192

5.  Suicide Attempts and Deaths in Sofala, Mozambique, From 2011 to 2014.

Authors:  Bradley H Wagenaar; Manuela Raunig-Berhó; Vasco Cumbe; Deepa Rao; Manuel Napúa; Kenneth Sherr
Journal:  Crisis       Date:  2016-06-01

Review 6.  Identification of strategies to prevent death after pesticide self-poisoning using a Haddon matrix.

Authors:  M Eddleston; N A Buckley; D Gunnell; A H Dawson; F Konradsen
Journal:  Inj Prev       Date:  2006-10       Impact factor: 2.399

7.  Pharmacokinetics of OpdA, an organophosphorus hydrolase, in the African green monkey.

Authors:  Colin J Jackson; Colin Scott; Angela Carville; Keith Mansfield; David L Ollis; Steven B Bird
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

8.  Use of OpdA, an organophosphorus (OP) hydrolase, prevents lethality in an African green monkey model of acute OP poisoning.

Authors:  Colin J Jackson; Angela Carville; Jeanine Ward; Keith Mansfield; David L Ollis; Tejvir Khurana; Steven B Bird
Journal:  Toxicology       Date:  2014-01-18       Impact factor: 4.221

Review 9.  Role of the calcium plateau in neuronal injury and behavioral morbidities following organophosphate intoxication.

Authors:  Laxmikant S Deshpande; Robert E Blair; Kristin F Phillips; Robert J DeLorenzo
Journal:  Ann N Y Acad Sci       Date:  2016-06-21       Impact factor: 5.691

10.  Post-exposure treatment with the oxime RS194B rapidly reactivates and reverses advanced symptoms of lethal inhaled paraoxon in macaques.

Authors:  Yvonne J Rosenberg; Jerry Wang; Tara Ooms; Narayanan Rajendran; Lingjun Mao; Xiaoming Jiang; Jonathan Lees; Lori Urban; Jeremiah D Momper; Yadira Sepulveda; Yan-Jye Shyong; Palmer Taylor
Journal:  Toxicol Lett       Date:  2017-11-09       Impact factor: 4.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.